

13th MILAN CONGRESS ON Innovative Anticancer Therapy



WEBINAR CONGRESS 2023

January 26th from 02.50 p.m. to 06.10 p.m.

January 27th from 03.30 p.m. to 06.20 p.m.



Fondazione IRCCS
Istituto Nazionale dei Tumori



Regione
Lombardia

Sistema Socio Sanitario

PATRONAGE REQUESTED



Sistema Socio Sanitario



Fondazione IRCCS
Istituto Nazionale dei Tumori



Regione
Lombardia



RATIONALE

The 13th "Milan Congress on Anticancer Innovative Therapy" Conference will involve leading international experts in the field of immuno-oncology and biologic therapy of cancer to improve the potential, opportunities and challenges of the new approaches.

The increasing knowledge of the molecular mechanisms responsible for neoplastic progression, the characterization of tumor microenvironment, and the immunological/angiogenetic mechanisms regulating the tumor-host interaction, allowed us to identify and apply more effective anti-cancer biologic and immunological treatments.

To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorithms of several different tumor types. The role of tumor metabolism and diet in tumor evolution and their impact on the outcomes of patients undergoing immunotherapy will be focused on.

This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy.

Finally, a wide spectrum of evolving topics in cancer research such as epigenetic drugs, nanoparticles and CART cell-based new constructs will be analyzed in view on introducing them to the clinical setting.



SCIENTIFIC HEADS

FILIPPO DE BRAUD (Milan, Italy)

MICHELE DEL VECCHIO (Milan, Italy)

MASSIMO DI NICOLA (Milan, Italy)

SCIENTIFIC BOARD

GIOVANNI APOLONE (Milan, Italy)

FILIPPO DE BRAUD (Milan, Italy)

MICHELE DEL VECCHIO (Milan, Italy)

MASSIMO DI NICOLA (Milan, Italy)

GIANPIETRO DOTTI (Chapel Hill, USA)

SOLDANO FERRONE (Boston, USA)

JOHN HISCOTT (Rome, Italy)



FACULTY

- **NINA BHARDWAY**, New York, NY, USA
- **FILIPPO DE BRAUD**, Milan, Italy
- **MICHELE DEL VECCHIO**, Milan, Italy
- **MASSIMO DI NICOLA**, Milan, Italy
- **SOLDANO FERRONE**, Boston, USA
- **FRANCESCO GALIMI**, Redwood City, CA, USA
- **JOHN HISCOTT**, Rome, Italy
- **FRANCO LOCATELLI**, Rome, Italy
- **MASSIMO MASSAIA**, Cuneo, Italy
- **FILIPPO PIETRANTONIO**, Milan, Italy
- **GIANCARLO PRUNERI**, Milan, Italy
- **CHRISTIAN ROLFO**, New York, NY, USA
- **RYAN SULLIVAN**, Boston, Italy
- **INGE MARIE SVANE**, Denmark



14:50 Introduction
Michele Del Vecchio (Milan, Italy)

I SESSION: Preclinical evidences and new targets
Chairmen: **Filippo de Braud** (Milan, Italy)
Soldano Ferrone (Boston, USA)

15.00-15.30 Overcoming innate-immune resistance in cancer
Nina Bhardwaj (New York, USA)

15.30-15.40 Discussion

15.40-16.10 The Liquid biopsy: state of the art in cancer diagnosis and prognosis
Christian Rolfo (New York, USA)

16.10-16.20 Discussion

16.20-16.50 Defining the role of targeted therapy in melanoma
Ryan Sullivan (Boston, USA)

16.50-17.00 Discussion

17.00-17.30 Role of omics to drive the discovery and the cure of solid tumors
Giancarlo Pruneri (Milan, Italy)

17.30-17.40 Discussion

Focus on Immunotherapy
17.40-18.10 Immunotherapy with anti-PD1 in solid tumors: a step forward?
Massimo Di Nicola (Milan, Italy)
Presented by **Michele Del Vecchio** (Milan, Italy)



II SESSION: Clinical translation

Chairmen: **Massimo Massaia** (Cuneo, Italy), **John Hiscott** (Rome, Italy)

15.30-16.00 CART cells in solid tumors: clinical results and perspective

Franco Locatelli (Rome, Italy)

16.00-16.10 Discussion

16.10-16.40 Adoptive cell therapy with TILs in solid tumors: clinical results

Inge Marie Svane (Denmark)

16.40-16.50 Discussion

16.50-17.20 MAYA clinical trial: Immuno-modulators and immunotherapy

Filippo Pietrantonio (Milan, Italy)

17.20-17.30 Discussion

17.30-18.00 Gamma/delta T cells: a step forward in adoptive therapy with CART cells

Francesco Galimi (Redwood City, USA)

18.00-18.10 Discussion

18.10-18.20 Conclusions

Massimo Di Nicola (Milan, Italy)



GENERAL INFORMATIONS

8

Date

Thursday, 26th January 2023 from 14.50 to 18.10

Friday, 27th January 2023 from 15.30 to 18.20

Webinar Congress on Nadirex Platform:

www.nadirex.org

Registration instructions

Registration is free and can be made on-line at

www.nadirex.org

The Congress is not by direct invitation of the Sponsor.

Official language

English

CME Provider Nr. 265

Organizing Secretariat



Nadirex International Srl

Via Riviera 39 · 27100 Pavia

Tel. +39.0382.525714/35 - Fax +39.0382.525736

Ref. Dr.ssa Gloria Molla - gloria.molla@nadirex.com

www.nadirex.com



GENERAL INFORMATIONS

Id ECM: 265-366625 - CME credits: Nr. 9

- **Learning hours:** 7
- **Educational goal:** Nr. 2 - Guidelines - Protocols - Procedures
- **Addresses of the Congress**

The Congress is addressed to the following figures:

- **Physician**
(Disciplines: Hematology, Infectious Diseases, Oncology, Internal Medicine, Transfusional Medicine)
- **Biologist**
- **Biotechnologist**
- **Biomedical Laboratory Technician**
- **Pharmacist** (Disciplines: Hospital Pharmacy)
- **Chemist** (Disciplines: Analytical Chemistry)
- **Participants:** 200
- **RL (Remote Learning) product type:** Live courses on dedicated multimedia platform (Virtual Classroom, Webinar) - Synchronous RL
- **Participant Resources Required:** email address (for registration), recent and updated web browser, Internet connection, devices to enable use of learning contents (pc, smartphone or tablet) with speakers (or earphones), microphone (only if the course calls for verbal interaction between teachers and participants).



GENERAL INFORMATIONS

Learning verification method

Online multiple-choice questionnaire with double randomization.

To earn ECM credits for the event you must:

- attend 90% of the teaching activities
- give correct answers to at least 75% of the questions on the questionnaire (a maximum of five attempts to pass the test are allowed, subject to repetition of content activities for each attempt);
- fill out the “RL evaluation form” and the “quality and learning needs questionnaire” (not mandatory)

Attention: the questionnaire will be online for only 3 (three) days after the event has concluded.

Guidelines for Speakers and Chairmen

The Zoom room will be opened only for speakers and chairmen at:

26th January: 02.00 p.m. - 27th January: 03.00 p.m.

(For participants room opens at the beginning time of the Congress)

The Official Language for the presentation of speakers is: English

The Official Language for the slides of the speakers is: English

The Official Language for chairmen is: English

Nadirex International assumes all responsibility for the contents, quality and ethical correctness of this ECM activity.

